BioNotebook: IPOs abound as Dicerna, Celladon launch; Puma seeks $115m; Omeros looks to Phase IIb
This article was originally published in Scrip
Executive Summary
It was a biotech IPO-palooza on 30 January as Dicerna Pharmaceuticals and Celladon took their initial public offerings to market, Ultragenyx increased the price range for its future IPO, Flexion Therapeutics set price terms for its offering, and Trevena reintroduced its prospective IPO.